Peritoneal tuberculosis remains a challenging clinical diagnosis for physicians, particularly when its imaging and clinical manifestations closely mimic advanced abdominal malignancy such as peritoneal carcinomatosis. According to peer-reviewed medical literature indexed in Cureus, this infectious mimicry frequently leads to diagnostic confusion, invasive exploratory procedures, and delayed appropriate treatment unless clinicians maintain a high index of suspicion for granulomatous disease.
Clinical Presentation and Diagnostic Overlap
Patients presenting with peritoneal tuberculosis often report constitutional symptoms including low-grade fever, night sweats, progressive abdominal distension, and significant weight loss. According to case studies published in medical journals like PubMed Central, these symptoms overlap significantly with ovarian, gastric, or primary peritoneal cancers. Physical examinations commonly reveal ascites and generalized abdominal tenderness. Imaging studies, including contrast-enhanced computed tomography (CT) scans, frequently demonstrate peritoneal thickening, omental caking, and nodular lesions that are radiologically indistinguishable from malignant peritoneal carcinomatosis.
Distinguishing Infection from Malignancy
Accurate differentiation between tuberculous peritonitis and peritoneal carcinomatosis requires rigorous diagnostic workup, as tumor markers such as CA-125 can be elevated in both conditions. According to clinical guidelines from the Centers for Disease Control and Prevention, diagnostic paracentesis with ascetic fluid analysis—evaluating adenosine deaminase (ADA) levels, lymphocyte predominance, and acid-fast bacilli (AFB) stains—provides essential early clues. However, definitive diagnosis frequently necessitates diagnostic laparoscopy with peritoneal biopsy for histological confirmation of caseating granulomas and positive mycobacterial cultures.
Therapeutic Management and Prognosis
Once confirmed via histopathology or microbiological testing, peritoneal tuberculosis responds exceptionally well to standard anti-tuberculosis pharmacotherapy without the need for radical surgical debulking. According to treatment frameworks outlined by the World Health Organization, standard regimens typically involve a multi-drug antimicrobial protocol consisting of isoniazid, rifampin, pyrazinamide, and ethambutol over a six-month course. Prompt initiation of medical therapy resolves symptoms rapidly and prevents long-term complications such as adhesive small bowel obstruction, underscoring the critical importance of distinguishing infectious mimics from true malignancies early in the evaluation process.
Related reading